Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, China.
Department of Immunology, Zibo Vocational Institute Health School, Zibo, Shandong 255000, China.
Chin Med J (Engl). 2021 Dec 10;135(2):194-204. doi: 10.1097/CM9.0000000000001558.
Despite improvements in disease diagnosis, treatment, and prognosis, breast cancer is still a leading cause of cancer death for women. Compelling evidence suggests that targeting cancer stem cells (CSCs) have a crucial impact on overcoming the current shortcomings of chemotherapy and radiotherapy. In the present study, we aimed to study the effects of T cells and a critical anti-tumor cytokine, interferon-gamma (IFN-γ), on breast cancer stem cells.
BALB/c mice and BALB/c nude mice were subcutaneously injected with 4T1 tumor cells. Tumor growth and pulmonary metastasis were assessed. ALDEFLOUR™ assays were performed to identify aldehyde dehydrogenasebright (ALDHbr) tumor cells. ALDHbr cells as well as T cells from tumor-bearing BALB/c mice were analyzed using flow cytometry. The effects of CD8+ T cells on ALDHbr tumor cells were assessed in vitro and in vivo. The expression profiles of ALDHbr and ALDHdim 4T1 tumor cells were determined. The levels of plasma IFN-γ were measured by enzyme-linked immunosorbent assay, and their associations with the percentages of ALDHbr tumor cells were evaluated. The effects of IFN-γ on ALDH expression and the malignancy of 4T1 tumor cells were analyzed in vitro.
There were fewer metastatic nodules in tumor-bearing BALB/c mice than those in tumor-bearing BALB/c nude mice (25.40 vs. 54.67, P < 0.050). CD8+ T cells decreased the percentages of ALDHbr 4T1 tumor cells in vitro (control vs. effector to target ratio of 1:1, 10.15% vs. 5.76%, P < 0.050) and in vivo (control vs. CD8+ T cell depletion, 10.15% vs. 21.75%, P < 0.001). The functions of upregulated genes in ALDHbr 4T1 tumor cells were enriched in the pathway of response to IFN-γ. The levels of plasma IFN-γ decreased gradually in tumor-bearing BALB/c mice, while the percentages of ALDHbr tumor cells in primary tumors increased. IFN-γ at a concentration of 26.68 ng/mL decreased the percentages of ALDHbr 4T1 tumor cells (22.88% vs. 9.88%, P < 0.050) and the protein levels of aldehyde dehydrogenase 1 family member A1 in 4T1 tumor cells (0.86 vs. 0.49, P < 0.050) and inhibited the abilities of sphere formation (sphere diameter <200 μm, 159.50 vs. 72.0; ≥200 μm, 127.0 vs. 59.0; both P < 0.050) and invasion (89.67 vs. 67.67, P < 0.001) of 4T1 tumor cells.
CD8+ T cells and IFN-γ decreased CSC numbers in a 4T1 mouse model of breast cancer. The application of IFN-γ may be a potential strategy for reducing CSCs in breast cancer.
尽管在疾病诊断、治疗和预后方面取得了进步,但乳腺癌仍是女性癌症死亡的主要原因。大量证据表明,靶向肿瘤干细胞(CSC)对于克服当前化疗和放疗的局限性具有至关重要的影响。在本研究中,我们旨在研究 T 细胞和一种关键的抗肿瘤细胞因子干扰素-γ(IFN-γ)对乳腺癌干细胞的影响。
将 4T1 肿瘤细胞皮下注射到 BALB/c 小鼠和 BALB/c 裸鼠中。评估肿瘤生长和肺转移情况。使用 ALDEFLOUR™ 分析鉴定醛脱氢酶阳性(ALDHbr)肿瘤细胞。使用流式细胞术分析荷瘤 BALB/c 小鼠的 ALDHbr 细胞和 T 细胞。评估 CD8+ T 细胞对 ALDHbr 肿瘤细胞的体外和体内作用。确定 ALDHbr 和 ALDHdim 4T1 肿瘤细胞的表达谱。通过酶联免疫吸附试验测量血浆 IFN-γ 水平,并评估其与 ALDHbr 肿瘤细胞百分比的相关性。分析 IFN-γ 对 4T1 肿瘤细胞 ALDH 表达和恶性程度的体外影响。
与荷瘤 BALB/c 裸鼠相比,荷瘤 BALB/c 小鼠的转移结节较少(25.40 比 54.67,P<0.050)。CD8+ T 细胞降低了 4T1 肿瘤细胞中 ALDHbr 的百分比,无论是在体外(对照与效应细胞比为 1:1,10.15%比 5.76%,P<0.050)还是在体内(对照与 CD8+ T 细胞耗竭,10.15%比 21.75%,P<0.001)。ALDHbr 4T1 肿瘤细胞上调基因的功能在对 IFN-γ 反应的途径中富集。荷瘤 BALB/c 小鼠的血浆 IFN-γ 水平逐渐下降,而原发肿瘤中 ALDHbr 肿瘤细胞的百分比增加。浓度为 26.68ng/mL 的 IFN-γ 降低了 4T1 肿瘤细胞中 ALDHbr 的百分比(22.88%比 9.88%,P<0.050)和 4T1 肿瘤细胞中醛脱氢酶 1 家族成员 A1 的蛋白水平(0.86 比 0.49,P<0.050),并抑制了 4T1 肿瘤细胞的球体形成能力(直径<200μm,159.50 比 72.0;≥200μm,127.0 比 59.0;均 P<0.050)和侵袭能力(89.67 比 67.67,P<0.001)。
CD8+ T 细胞和 IFN-γ 在乳腺癌的 4T1 小鼠模型中减少了 CSC 数量。IFN-γ 的应用可能是减少乳腺癌中 CSC 的一种潜在策略。